[A19-71] Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2019
Commission awarded on 28.08.2019 by the Federal Joint Committee (G-BA).
Airways and respiratory system
Cystic fibrosis in patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.